TransMedics Group (NASDAQ:TMDX) Receives "Hold" Rating from Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating restated by equities research analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports.

Separately, Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Stock Down 3.4 %

Shares of NASDAQ TMDX traded down $3.18 during midday trading on Wednesday, reaching $90.32. The company's stock had a trading volume of 633,112 shares, compared to its average volume of 1,351,081. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a 50 day simple moving average of $74.46 and a 200-day simple moving average of $77.42. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of 95.89 and a beta of 2.14.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of TransMedics Group in the third quarter worth about $436,000. Morse Asset Management Inc purchased a new stake in shares of TransMedics Group in the 3rd quarter worth about $823,000. Sanctuary Advisors LLC raised its position in shares of TransMedics Group by 63.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company's stock worth $634,000 after acquiring an additional 1,568 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in TransMedics Group in the third quarter worth $149,000. Finally, Principal Financial Group Inc. raised its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock worth $31,759,000 after purchasing an additional 146,115 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.